QURE

AI MemoPost-earnings T+3

uniQure

As of 2026-05-15/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

AMT-260 first-cohort epilepsy update at the Epilepsy Foundation Pipeline Conference • 2026-06-18

Base target: $30 / p=50% prob

Biggest risk

The key post-print overhang did not change: FDA said existing Phase I/II data versus external control are not sufficient as primary evidence of effectiveness for AMT-130, implying a potentially longer and costlier U.S. path even if UK progress continues [#8-K-2026-05-05]. Delayed sell-side reaction was thin; the only concrete checked revision was H.C. Wainwright lowering its target to $50 from $70 while keeping a Buy rating, which is supportive but not broad confirmation.

Invalidation

Break below $20 or thesis failure.

What would change my mind?

The company source supports a still-constructive monitoring thesis: AMT-130 retains an active regulatory path, the UK filing remains targeted for Q3 2026, AMT-260 has a dated June catalyst, and cash runway into 2H29 reduces immediate financing pressure [#8-K-2026-05-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-05-15

Base target

$30

p=50%

Bull target

$36

p=25%

Bear target

$20

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion tests whether Q1 updates can hold the stock above pre-print levels
The company source supports a still-constructive monitoring thesis: AMT-130 retains an active regulatory path, the UK filing remains targeted for Q3 2026, AMT-260 has a dated June catalyst, and cash runway into 2H29 reduces immediate financing pressure [#8-K-2026-05-05].
At the $27.75 anchor, shares sit just below the packet's mean/median analyst target of about $28.67, so baseline sell-side valuation does not show large obvious upside.

BearKey bullets

AMT-191 has dose-limiting toxicity concerns: additional mid- and high-dose dosing remains paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations in two patients [#8-K-2026-05-05].
External analyst and news coverage remains thin, which lowers confidence in post-earnings read-through and makes sentiment more headline-sensitive.
FDA feedback remains the central risk because the agency would not agree current AMT-130 Phase I/II data against external control are sufficient for primary evidence of effectiveness, raising the odds of a new study and a longer U.S.

WatchKey bullets

AMT-260 first-cohort epilepsy update at the Epilepsy Foundation Pipeline Conference

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $30 (p=50%)

Target spread vs base: +20% / -33%

Scenario probabilities

Bull Target: $36 (p=25%)Base Target: $30 (p=50%)Bear Target: $20 (p=25%)

Commentary

Tone remains cautiously constructive but monitoring-oriented rather than fully bullish. The primary May 5 company update confirmed milestone timing and a long cash runway, and QURE closed at $27.75 on May 14, 2026 with shares at $27.22 intraday on May 15, 2026, suggesting the post-print reaction has not collapsed. Still, delayed analyst-revision evidence is sparse, consensus/revenue-surprise reporting is mostly from secondary earnings pages, and low coverage means the stock can stay volatile around each AMT-130 and AMT-260 headline.

As of 2026-05-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion tests whether Q1 updates can hold the stock above pre-print levels

Scenarios

Bull Target (Scenario probability)

$36 / p=25% prob

Base Target (Scenario probability)

$30 / p=50% prob

Bear Target (Scenario probability)

$20 / p=25% prob

Analysis 2026-05-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-18
AMT-260 first-cohort epilepsy update at the Epilepsy Foundation Pipeline Conference
uniQure said it expects to present Phase I/IIa data from the first six AMT-260 patients with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026, giving investors a nearer-term clinical readout outside Huntington's disease [#8-K-2026-05-05].
Prob 80.00% • Move 12.00% • Priced-in 35.00%
EVENT2026-06-30
AMT-130 regulatory path clarity from FDA Type B meeting and UK filing track
Management said a Type B FDA meeting is scheduled for Q2 2026 to discuss a potential new AMT-130 trial design and the statistical analysis plan for the four-year data expected in Q3 2026, while a UK MAA remains on track for Q3 2026 after a constructive MHRA pre-submission meeting [#8-K-2026-05-05] [#10-Q-2026-05-05]. This remains the highest-value catalyst because U.S. approval evidence requirements are still unsettled.
Prob 70.00% • Move 16.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion tests whether Q1 updates can hold the stock above pre-print levels
2026-05-20
The May 5 earnings update kept the core AMT-130, AMT-260 and cash-runway milestones intact, with $586.6 million of cash, cash equivalents and current investment securities and runway into the second half of 2029, while Q1 revenue was $3.6 million and net loss was $53.5 million [#8-K-2026-05-05] [#10-Q-2026-05-05]. Secondary post-print coverage is thin; one checked earnings page showed a modest EPS beat versus consensus but a revenue miss, and delayed analyst revision evidence remained sparse, so near-term sentiment likely depends on whether investors focus on runway and milestone cadence rather than the still-lossmaking profile.
Prob 65% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

AMT-191 has dose-limiting toxicity concerns: additional mid- and high-dose dosing remains paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations in two patients [#8-K-2026-05-05].
External analyst and news coverage remains thin, which lowers confidence in post-earnings read-through and makes sentiment more headline-sensitive.
FDA feedback remains the central risk because the agency would not agree current AMT-130 Phase I/II data against external control are sufficient for primary evidence of effectiveness, raising the odds of a new study and a longer U.S. timeline [#8-K-2026-05-05].
Q1 still showed a $53.5 million net loss and SG&A stepped up materially due in part to commercial-planning hires, so execution against runway assumptions matters even with cash into 2H29 [#8-K-2026-05-05].
uniQure discontinued AMT-162 development after preliminary EPISOD1 safety and efficacy review, reducing pipeline breadth and increasing concentration on AMT-130 execution [#8-K-2026-05-05].

Peers

Symbol	Summary
AGIO	Agios is a nearer rare-disease biotech operating benchmark than large-cap pharma, but it is not a direct gene-therapy comp; it helps frame runway, pipeline-prioritization and commercialization-execution expectations rather than AMT-130-specific read-throughs.
CAPR	Capricor is the closest packet peer for small-cap clinical/regulatory biotech risk, though modality and disease focus differ; it is more useful as a catalyst-volatility benchmark than a direct valuation read-through peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-15